BR112012000098A2 - Processo para identificação de compostos para tratar câncer - Google Patents

Processo para identificação de compostos para tratar câncer

Info

Publication number
BR112012000098A2
BR112012000098A2 BRBR112012000098-5A BR112012000098A BR112012000098A2 BR 112012000098 A2 BR112012000098 A2 BR 112012000098A2 BR 112012000098 A BR112012000098 A BR 112012000098A BR 112012000098 A2 BR112012000098 A2 BR 112012000098A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
identifying compounds
identifying
compounds
cancer
Prior art date
Application number
BRBR112012000098-5A
Other languages
English (en)
Other versions
BR112012000098B1 (pt
Inventor
Maria Soledad Soengas Gonzalez
Damia Tormo Carulla
Original Assignee
Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii filed Critical Fundacion Ct Nac De Investigaciones Cardiovasculares Carlos Iii
Publication of BR112012000098A2 publication Critical patent/BR112012000098A2/pt
Publication of BR112012000098B1 publication Critical patent/BR112012000098B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
BR112012000098-5A 2009-07-04 2010-07-05 Processo para a identificação de compostos para tratar câncer BR112012000098B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200930417 2009-07-04
ES200930417A ES2368963B1 (es) 2009-07-04 2009-07-04 Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
PCT/EP2010/059593 WO2011003883A1 (en) 2009-07-04 2010-07-05 Process for the identification of compounds for treating cancer

Publications (2)

Publication Number Publication Date
BR112012000098A2 true BR112012000098A2 (pt) 2014-10-07
BR112012000098B1 BR112012000098B1 (pt) 2019-03-06

Family

ID=42556459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000098-5A BR112012000098B1 (pt) 2009-07-04 2010-07-05 Processo para a identificação de compostos para tratar câncer

Country Status (18)

Country Link
US (5) US20120172581A1 (pt)
EP (1) EP2452189B1 (pt)
JP (2) JP5908398B2 (pt)
KR (1) KR101877840B1 (pt)
CN (3) CN110974842B (pt)
AU (1) AU2010270291B2 (pt)
BR (1) BR112012000098B1 (pt)
CA (1) CA2767148C (pt)
DK (1) DK2452189T3 (pt)
ES (2) ES2368963B1 (pt)
IL (1) IL217310A (pt)
MX (1) MX2012000280A (pt)
NZ (1) NZ597793A (pt)
PL (1) PL2452189T3 (pt)
PT (1) PT2452189E (pt)
SG (1) SG177482A1 (pt)
WO (1) WO2011003883A1 (pt)
ZA (1) ZA201200116B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154944A2 (en) * 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
RU2771104C2 (ru) 2014-05-14 2022-04-26 Таргиммьюн Терапьютикс Аг Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
MX2017013321A (es) 2015-04-22 2018-07-06 Curevac Ag Composicion que contiene arn para tratamiento de enfermedades tumorales.
CN112294757B (zh) 2015-11-17 2024-02-13 亮点医疗有限责任公司 包含含有双链聚核糖核苷酸与聚亚烷基亚胺的复合物的粒子的医药组合物
CN107198777A (zh) * 2016-04-01 2017-09-26 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
US10849921B2 (en) 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN109200056A (zh) * 2018-11-20 2019-01-15 苏州系统医学研究所 聚肌胞在防治胰腺炎及其相关病症中的用途
JP2022507840A (ja) 2018-11-21 2022-01-18 ハイライト セラピューティクス エセ.エレ. ナノプレックス化ポリ(i:c)製剤及びその使用
CN111166769B (zh) * 2020-03-18 2022-01-11 山东大学 真皮成纤维细胞在治疗黑色素瘤中的应用
WO2022111829A1 (en) 2020-11-30 2022-06-02 Symrise Ag Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes
CN113413460A (zh) * 2021-08-10 2021-09-21 中山大学·深圳 Traf6抑制剂在制备黑色素瘤药物中的应用
KR20240038468A (ko) * 2022-09-16 2024-03-25 재단법인 아산사회복지재단 자가포식 조절제를 스크리닝하는 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124702A (en) * 1971-07-06 1978-11-07 Merck & Co., Inc. Polynucleotides active as inducers of interferon production in living animal cells
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
WO2003068936A2 (en) * 2002-02-14 2003-08-21 Research Development Foundation Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
US7927792B2 (en) * 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
CA2548992A1 (en) * 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
US20080220416A1 (en) * 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
US20050265997A1 (en) * 2004-05-26 2005-12-01 Wisconsin Alumni Research Foundation Cancer treatment method by inhibiting MAGE gene expression or function
WO2006119619A1 (en) * 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
CN101182517A (zh) * 2007-12-18 2008-05-21 广州拓谱基因技术有限公司 用于疾病治疗的多靶点鸡尾酒双链小干扰rna及其制备方法

Also Published As

Publication number Publication date
MX2012000280A (es) 2012-12-05
SG177482A1 (en) 2012-02-28
US20140154202A1 (en) 2014-06-05
RU2012103902A (ru) 2013-08-20
KR101877840B1 (ko) 2018-08-09
AU2010270291B2 (en) 2014-10-09
ES2368963A1 (es) 2011-11-24
US20190117685A1 (en) 2019-04-25
BR112012000098B1 (pt) 2019-03-06
PT2452189E (pt) 2014-01-22
IL217310A (en) 2017-05-29
JP2012531193A (ja) 2012-12-10
CA2767148C (en) 2019-05-28
JP6222749B2 (ja) 2017-11-01
CN102483404A (zh) 2012-05-30
US20120172581A1 (en) 2012-07-05
NZ597793A (en) 2013-05-31
ZA201200116B (en) 2012-09-26
EP2452189B1 (en) 2013-10-16
CN104857016B (zh) 2019-12-24
US20170020917A1 (en) 2017-01-26
CN110974842A (zh) 2020-04-10
JP5908398B2 (ja) 2016-04-26
CN110974842B (zh) 2023-09-19
CN104857016A (zh) 2015-08-26
PL2452189T3 (pl) 2014-05-30
AU2010270291A1 (en) 2012-02-16
ES2368963B1 (es) 2012-10-10
DK2452189T3 (da) 2014-01-20
IL217310A0 (en) 2012-02-29
JP2016104744A (ja) 2016-06-09
EP2452189A1 (en) 2012-05-16
WO2011003883A1 (en) 2011-01-13
CA2767148A1 (en) 2011-01-13
ES2442623T3 (es) 2014-02-12
KR20120055550A (ko) 2012-05-31
US20190134077A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
BR112012000098A2 (pt) Processo para identificação de compostos para tratar câncer
SMT201400100B (it) Processo migliorato
BRPI1010759A2 (pt) processo para produção de proteína
BRPI1011702A2 (pt) processo para preparação de poliéster insaturado
BR112012000822A2 (pt) processo
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BR112012028514A2 (pt) composição para o tratamento da água residual e processo para o tratamento de água residual
BR112012012338A2 (pt) processo
BRPI0919241A8 (pt) processo para fabricação de compostos de quinolona
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI0909004A2 (pt) Processo para produção de biogás
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0921420A2 (pt) processo para preparar compostos
BRPI1012134A2 (pt) processo de carbolinação
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI1007573A2 (pt) processo
BRPI0920689A2 (pt) processo para produção de cumeno
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BR112012029016A2 (pt) processo de redução direta
BRPI0911992A2 (pt) processo para preparação de bifenilanilidas substituídas
BR112012003642A2 (pt) processo
BRPI0915177A2 (pt) processo para fazer 2-amino-tiazolonas substituídas

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2010, OBSERVADAS AS CONDICOES LEGAIS.